Regeneron Pharmaceuticals, Inc. announced that it has elected Tony Coles, M.D., to its Board of Directors.  Dr. Coles was nominated to become a member of the Regeneron Board by Sanofi. Under the terms of an investor agreement between Regeneron and Sanofi, Sanofi gained the right to nominate a single independent director to the Regeneron Board when it reached 20% ownership of Regeneron's total outstanding capital stock.